ABSTRACT
Atopic dermatitis (AD) is the most common chronic skin inflammatory disease, with a profound impact on patients' quality of life. AD varies considerably in clinical course, age of onset and degree to which it is accompanied by allergic and non-allergic comorbidities. Skin barrier impairment in both lesional and nonlesional skin is now recognized as a critical and often early feature of AD. This may be explained by a number of abnormalities identified within both the stratum corneum and stratum granulosum layers of the epidermis. The goal of this review is to provide an overview of key barrier defects in AD, starting with a historical perspective. We will also highlight some of the commonly used methods to characterize and quantify skin barrier function. There is ample opportunity for further investigative work which we call out throughout this review. These include: quantifying the relative impact of individual epidermal abnormalities and putting this in a more holistic view with physiological measures of barrier function, as well as determining whether these barrier-specific endotypes predict clinical phenotypes (e.g. age of onset, natural history, comorbidities, response to therapies, etc). Mechanistic studies with new (and in development) AD therapies that specifically target immune pathways, Staphylococcus aureus abundance and/or skin barrier will help us understand the dynamic crosstalk between these compartments and their relative importance in AD.
Subject(s)
Dermatitis, Atopic/immunology , Epidermis/immunology , Animals , Disease Progression , Humans , Quality of Life , Severity of Illness IndexABSTRACT
OBJECTIVE: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, and it has serious effects on children's and families' quality of life. We aimed to screen and evaluate the efficacy of different formulas on relieving of atopic dermatitis clinical symptoms by developing an eczema-like reconstructed human skin equivalent in vitro. METHOD: Some research has reported that thymic stromal lymphopoietin (TSLP) may be a potential therapeutic target for the treatment of AD. We developed an eczema-like in vitro skin equivalent by coculturing the cocktails polyinosinic-polycytidylic acid sodium salt (poly(I:C)) and lipopolysaccharides (LPS). The eczema-like skin equivalent was characterized by overexpression of TSLP and impaired skin barrier function. Three cosmetic formulas with the potential of anti-inflammation and skin barrier promotion were topically applied onto the eczema-like skin equivalent, mimicking in vivo application. The inhibitory effect on TSLP was examined by ELISA. Effects on tissue viability and skin barrier function were determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) method. CONCLUSION: The results show that eczema-like skin equivalent induced by cocktails of poly(I:C) and LPS can mimic the skin characters of the atopic dermatitis. The cocktails can induce high TSLP expression, impaired cell viability, and skin barrier function. The cosmetic formulas with the potential of anti-inflammation and skin barrier promotion were evaluated to be helpful to decrease and relieve the impact of AD with the decreased TSLP and the higher tissue viability than the eczema-like skin equivalent without any cosmetic application. The eczema-like skin equivalent can be used to screen and evaluate formulas on AD relieving.
Subject(s)
Anti-Inflammatory Agents/administration & dosage , Cosmeceuticals/administration & dosage , Dermatitis, Atopic/drug therapy , Epidermis/drug effects , Cell Culture Techniques , Child , Coculture Techniques , Culture Media/pharmacology , Cytokines/metabolism , Dermatitis, Atopic/immunology , Drug Evaluation, Preclinical/methods , Epidermis/immunology , Epidermis/metabolism , Humans , Keratinocytes/drug effects , Keratinocytes/immunology , Keratinocytes/metabolism , Lipopolysaccharides/pharmacology , Permeability/drug effects , Poly I-C/pharmacologyABSTRACT
Atopic dermatitis is a common inflammatory skin disease caused by the interaction of genetic and environmental factors. By allelic copy number analysis at missense single-nucleotide polymorphisms on 26 genes with copy number variation, we identified a significant association between atopic dermatitis and human KPRP. Human KPRP expression, which was localized to the upper granular layer of epidermis, was significantly decreased in atopic dermatitis compared with normal skin. KPRP was histologically colocalized with loricrin and was mainly detected in cytoskeleton fractions of human keratinocytes. To further investigate the role of KPRP in skin, Kprp-knockout mice were generated. Heterozygous knockout (Kprp+/-) mice exhibited reduced KPRP expression to level a similar to that of human AD lesional skin. Kprp+/- mice showed abnormal desmosome structure and detachment of lower layers of the stratum corneum. Percutaneous inflammation by topical application of croton oil or oxazolone was enhanced, and epicutaneous immunization with ovalbumin induced a high level of IgE in Kprp+/- mice. Our study, started from allelic copy number analysis in human AD, identified the importance of KPRP, the decrease of which leads to barrier dysfunction.
Subject(s)
Cytoskeletal Proteins/genetics , Dermatitis, Atopic/genetics , Epidermis/pathology , Intracellular Signaling Peptides and Proteins/genetics , Keratinocytes/pathology , Proteins/genetics , Adjuvants, Immunologic/administration & dosage , Animals , Case-Control Studies , Croton Oil/immunology , Cytoskeletal Proteins/deficiency , DNA Copy Number Variations , Dermatitis, Atopic/chemically induced , Dermatitis, Atopic/immunology , Dermatitis, Atopic/pathology , Desmosomes/pathology , Desmosomes/ultrastructure , Disease Models, Animal , Epidermis/drug effects , Epidermis/immunology , Humans , Intracellular Signaling Peptides and Proteins/deficiency , Keratinocytes/drug effects , Keratinocytes/immunology , Mice , Mice, Knockout , Microscopy, Electron, Transmission , Oxazolone/immunology , Proteins/metabolism , Water Loss, Insensible/geneticsABSTRACT
BACKGROUND: Psoriasis is a multi-systemic inflammatory disease that results from dysregulation between epidermal keratinocyte homeostasis and both innate and acquired immunity. Epidermal barrier defect has been described in psoriatic lesions. Furthermore an imbalance between pro-oxidative stress and antioxidant defense mechanisms are known in psoriasis patients. AIM: The aim of this study was to address the link between disease activity, epidermal barrier and systemic oxidative stress in the course of 311â¯nm narrow band ultraviolet B (NB-UVB) therapy of psoriasis. The dynamic of systemic oxidative stress parameters as well as local transepidermal water loss (TEWL) and stratum corneum hydration (SCH) was characterized before and after 311â¯nm NB-UVB therapy on the plaques of psoriasis vulgaris in comparison to untreated non-affected volar forearm sites of the same patients. MATERIAL AND METHODS: 22 patients with plaque type psoriasis vulgaris and 25 gender- and age-matched healthy controls were enrolled. We assessed the psoriasis area and severity index (PASI) and the dermatology life quality index (DLQI) for monitoring disease activity, severity and self-perceived DLQI impact as patient related outcome parameter. We measured non-invasively TEWL (Tewameter TM 300) and SCH (Corneometer CM 825) and the end product of lipid peroxidation - malondialdehyde (MDA), Reactive oxygen species (ROS), ascorbyl radicals (Asc) and detoxifying activity of catalase (CAT) were measured in the peripheral blood with spectrophotometric and EPR spectroscopy methods. RESULTS: Disease activity improved in all patients compared to baseline witnessed by significant decrease in PASI; (from 14.1 to 10.4; pâ¯<â¯0.0001) and DLQI (from 11.7 to 8.1; pâ¯<â¯0.0001). At baseline TEWL-values were significantly (pâ¯<â¯0.0001) higher on psoriatic plaques (16.8â¯g/h/m2) in comparison to uninvolved skin (5.3â¯g/h/m2); with a decrease at both sites after NB-UVB phototherapy. SCH was significantly lower at psoriatic plaque s (4.7AU) compared to uninvolved sskin (42.4AU) and increased after treatment (8.6AU) (pâ¯<â¯0.0001). Interestingly, SCH decrease slightly during therapy at uninvolved skin (40.6AU). ROS and Asc declined during therapy in parallel to a decrease in MDA. A mild decrease in the antioxidative enzyme CAT activity which did not reach the significance was observed. CONCLUSION: The presented data is shows that a clinical improvement of psoriatic plaques under NB-UVB therapy, shown in with a decreased PASI and reflected by an increase in quality of life has beneficial effects on epidermal barrier function, SCH and improvement of systemic oxidative stress parameters (ROS, MDA and Asc). We assume that the general improvement in the oxidative stress parameters along with epidermal barrier parameters reflects mainly the improvement of disease activity which overwrites the possible negative pro-oxidative effects of the UV treatment.
Subject(s)
Epidermis/radiation effects , Oxidative Stress/radiation effects , Psoriasis/radiotherapy , Ultraviolet Therapy/methods , Adult , Antioxidants/metabolism , Case-Control Studies , Epidermal Cells , Epidermis/immunology , Epidermis/pathology , Female , Free Radicals/blood , Healthy Volunteers , Humans , Keratinocytes/pathology , Keratinocytes/radiation effects , Male , Middle Aged , Psoriasis/blood , Psoriasis/immunology , Psoriasis/pathology , Quality of Life , Severity of Illness Index , Treatment Outcome , Water Loss, Insensible/radiation effectsABSTRACT
Psoriasis is a chronic inflammatory skin disease characterized by the infiltration of T cell and other immune cells to the skin in response to injury or autoantigens. Conventional, as well as unconventional, γδ T cells are recruited to the dermis and epidermis by CCL20 and other chemokines. Together with its receptor CCR6, CCL20 plays a critical role in the development of psoriasiform dermatitis in mouse models. We screened a panel of CCL20 variants designed to form dimers stabilized by intermolecular disulfide bonds. A single-atom substitution yielded a CCL20 variant (CCL20 S64C) that acted as a partial agonist for the chemokine receptor CCR6. CCL20 S64C bound CCR6 and induced intracellular calcium release, consistent with G-protein activation, but exhibited minimal chemotactic activity. Instead, CCL20 S64C inhibited CCR6-mediated T cell migration with nominal impact on other chemokine receptor signaling. When given in an IL-23-dependent mouse model for psoriasis, CCL20 S64C prevented psoriatic inflammation and the up-regulation of IL-17A and IL-22. Our results validate CCR6 as a tractable therapeutic target for psoriasis and demonstrate the value of CCL20 S64C as a lead compound.
Subject(s)
Chemokine CCL20/genetics , Dermatitis/therapy , Mutagenesis, Site-Directed/methods , Psoriasis/therapy , Receptors, CCR6/metabolism , Animals , Biological Therapy/methods , COS Cells , Chemokine CCL20/immunology , Chemokine CCL20/metabolism , Chlorocebus aethiops , Crystallography, X-Ray , Dermatitis/immunology , Disease Models, Animal , Epidermis/immunology , Epidermis/metabolism , Humans , Interleukin-23/immunology , Mice , Psoriasis/immunology , Receptors, CCR6/immunology , T-Lymphocytes/immunologyABSTRACT
Atopic dermatitis (AD) is a chronic inflammatory skin condition that requires a manifold approach to therapy. The goal of therapy is to restore the function of the epidermal barrier and to reduce skin inflammation. This can be achieved with skin moisturization and topical anti-inflammatory agents, such as topical corticosteroids and calcineurin inhibitors. Furthermore, proactive therapy with twice weekly use of both topical corticosteroids and calcineurin inhibitors in previously affected areas has been found to reduce the time to the next eczematous flare. Adjunctive treatment options include wet wrap therapy, anti-histamines, and vitamin D supplementation. Bacterial colonization, in particular Staphylococcus aureus, can contribute to eczematous flares and overt infection. Use of systemic antibiotics in infected lesions is warranted; however, empiric antibiotics use in uninfected lesions is controversial. Local antiseptic measures (i.e., bleach baths) and topical antimicrobial therapies can be considered in patients with high bacterial colonization. Difficult-to-treat AD is a complex clinical problem that may require re-evaluation of the initial diagnosis of AD, especially if the onset of disease occurs in adulthood. It may also necessitate evaluation for contact, food, and inhaled allergens that may exacerbate the underlying AD. There are a host of systemic therapies that have been successful in patients with difficult-to-treat AD, however, these agents are limited by their side effect profiles. Lastly, with further insight into the pathophysiology of AD, new biological agents have been investigated with promising results.
Subject(s)
Adrenal Cortex Hormones/therapeutic use , Eczema/therapy , Adrenal Cortex Hormones/administration & dosage , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Calcineurin Inhibitors/administration & dosage , Calcineurin Inhibitors/therapeutic use , Combined Modality Therapy , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/therapy , Dermatitis, Contact/diagnosis , Dermatitis, Contact/therapy , Desensitization, Immunologic , Disease Management , Eczema/diagnosis , Eczema/etiology , Eczema/metabolism , Epidermis/drug effects , Epidermis/immunology , Epidermis/pathology , Histamine Antagonists/administration & dosage , Histamine Antagonists/therapeutic use , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Phototherapy/methodsABSTRACT
Cry j1 is the major peptide allergen of Japanese cedar (Sugi), Cryptomeria japonica. Since some allergens disrupt epidermal permeability barrier homeostasis, we hypothesized that Cry j1 might have a similar effect. Intracellular calcium level in cultured human keratinocytes was measured with a ratiometric fluorescent probe, Fura-2 AM. Application of Cry j1 significantly increased the intracellular calcium level of keratinocytes, and this increase was inhibited by trypsin inhibitor or a protease-activated receptor 2 (PAR-2) antagonist. We found that Cry j1 itself did not show protease activity, but application of Cry j1 to cultured keratinocytes induced a rapid (within 30 s) and transient increase of protease activity in the medium. This transient increase was blocked by trypsin inhibitor or PAR-2 antagonist. The effect of Cry j1 on transepidermal water loss (TEWL) of cultured human skin was measured in the presence and absence of a trypsin inhibitor and PAR-2 antagonist. Cry j1 significantly impaired the barrier function of human skin ex vivo, and this action was blocked by co-application of trypsin inhibitor or PAR-2 antagonist. Our results suggested that interaction of Cry j1 with epidermal keratinocytes leads to the activation of PAR-2, which induces elevation of intracellular calcium and disruption of barrier function. Blocking the interaction of Cry j1 with epidermal keratinocytes might ameliorate allergic reaction and prevent disruption of epidermal permeability barrier homeostasis.
Subject(s)
Allergens/immunology , Antigens, Plant/immunology , Calcium/metabolism , Epidermis/pathology , Keratinocytes/metabolism , Plant Proteins/immunology , Tight Junctions/pathology , Cells, Cultured , Cryptomeria/immunology , Epidermis/immunology , Humans , Hypersensitivity/immunology , Organ Culture Techniques , Peptide Hydrolases/metabolism , Plant Proteins/metabolism , Pollen/immunology , Protease Inhibitors/metabolism , Receptor, PAR-2/metabolism , Tight Junctions/immunologyABSTRACT
This study was conducted to evaluate the effects of garlic supplementation on some skin mucus immune parameters, mucus antimicrobial activity and growth performance of the Caspian roach (Rutilus rutilus caspicus) fry. Fish (1 ± 0.07 g) were divided into four groups fed diets containing 0 (control), 5, 10 and 15 g kg(-1) garlic for 8 weeks. The results showed that there was a significant increase in weight gain and specific growth rate in those fish fed garlic diets compared with the control (P < 0.05). Condition factor was not significantly affected by garlic dosage. At the end of trial, the epidermal mucus protein level, alkaline phosphatase and antimicrobial activity against 2 g-negative bacteria (Escherichia coli and Serratia marcescens) and gram-positive bacteria (Streptococcus faecium and Micrococcus luteus) were measured. Skin mucus alkaline phosphatase, protein levels and antimicrobial activity were increased following garlic administration, and the bacterial growth inhibition zones were significantly elevated in garlic-fed fish (P < 0.05). In salinity stress experiment, no differences were observed for survival rate among the experimental diets. No mortality was recorded during the feeding trial. These results indicated that dietary garlic beneficially affects the skin mucus immune parameters and growth performance of the Caspian roach fry.
Subject(s)
Cyprinidae/physiology , Diet/veterinary , Dietary Supplements , Garlic , Mucus/immunology , Mucus/microbiology , Animal Feed/analysis , Animals , Cyprinidae/growth & development , Cyprinidae/immunology , Dose-Response Relationship, Drug , Enterococcus faecium/physiology , Epidermis/drug effects , Epidermis/immunology , Escherichia coli/physiology , Garlic/chemistry , Immunity, Mucosal/immunology , Micrococcus luteus/physiology , Salinity , Serratia marcescens/physiology , Stress, Physiological/drug effectsABSTRACT
Epidermal keratinocytes provide protective role against external stimuli by barrier formation. In addition, kertinocytes exerts their role as the defense cells via activation of innate immunity. Disturbance of keratinocyte functions is related with skin disorders. Psoriasis is a common skin disease related with inflammatory reaction in epidermal cells. We attempted to find therapeutics for psoriasis, and found that Paeonia lactiflora Pallas extract (PE) has an inhibitory potential on poly (I:C)-induced inflammation of keratinocytes. PE significantly inhibited poly (I:C)-induced expression of crucial psoriatic cytokines, such as IL-6, IL-8, CCL20 and TNF-α, via down-regulation of NF-κB signaling pathway in human keratinocytes. In addition, PE significantly inhibited poly (I:C)-induced inflammasome activation, in terms of IL-1ß and caspase-1 secretion. Finally, PE markedly inhibited poly (I:C)-increased NLRP3, an important component of inflammasome. These results indicate that PE has an inhibitory effect on poly (I:C)-induced inflammatory reaction of keratinocytes, suggesting that PE can be developed for the treatment of psoriasis.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Dermatologic Agents/pharmacology , Epidermis/drug effects , Keratinocytes/drug effects , Paeonia , Plant Extracts/pharmacology , Poly I-C/pharmacology , Psoriasis/drug therapy , Anti-Inflammatory Agents/isolation & purification , Carrier Proteins/metabolism , Cell Line , Cytokines/metabolism , Dermatologic Agents/isolation & purification , Dose-Response Relationship, Drug , Epidermis/immunology , Epidermis/metabolism , Humans , Immunity, Innate/drug effects , Inflammasomes/drug effects , Inflammasomes/metabolism , Inflammation Mediators/metabolism , Keratinocytes/immunology , Keratinocytes/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein , Paeonia/chemistry , Phytotherapy , Plant Extracts/isolation & purification , Plants, Medicinal , Psoriasis/immunology , Psoriasis/metabolismABSTRACT
Narrow-band UVB (NB-UVB) phototherapy is commonly used for treatment of psoriasis, though the mechanisms underlying its efficacy have not been completely elucidated. We used gene expression profiling to characterise gene expression in lesional epidermis from psoriasis patients in the middle and late stages of NB-UVB photo-therapy. Increased melanogenesis gene expression was the earliest response to phototherapy. At the end of treatment, genes responding to phototherapy and correlated to treatment outcome were involved in oxidation reduction, growth and mitochondria organisation. Particularly, SPATA18, a key regulator of mitochondrial quality, was significantly down-regulated in psoriasis (p < 0.05). Poly(dA:dT) and poly(I:C) stimulation increased SPATA18 level in primary keratinocytes, indicating the importance of mitochondria quality control under innate immune induced oxidative stress. Normalised SPATA18 expression after phototherapy indicates improved mitochondrial quality control and restored cellular redox status. Our data suggest that oxidation reduction is critical for the resolution of psoriatic plaques following NB-UVB phototherapy.
Subject(s)
Epidermis/radiation effects , Keratinocytes/radiation effects , Psoriasis/radiotherapy , Ultraviolet Therapy/methods , Biopsy , Cell Line , Discriminant Analysis , Epidermis/immunology , Epidermis/metabolism , Gene Expression Profiling/methods , Gene Expression Regulation , Humans , Keratinocytes/drug effects , Keratinocytes/immunology , Keratinocytes/metabolism , Least-Squares Analysis , Melanins/biosynthesis , Mitochondria/immunology , Mitochondria/metabolism , Mitochondria/radiation effects , Mitochondrial Proteins/genetics , Mitochondrial Proteins/metabolism , Oxidation-Reduction , Poly I-C/pharmacology , Poly dA-dT/pharmacology , Psoriasis/genetics , Psoriasis/immunology , Psoriasis/metabolism , Time Factors , Treatment OutcomeABSTRACT
The skin is the largest organ of the body, providing a protective barrier against bacteria, chemicals and physical insults while maintaining homeostasis in the internal environment. Such a barrier function the skin ensures protection against excessive water loss. The skin's immune defence consists of several facets, including immediate, non-specific mechanisms (innate immunity) and delayed, stimulus-specific responses (adaptive immunity), which contribute to fending off a wide range of potentially invasive microorganisms. This article is an overview of all known data about 'fragile skin'. Fragile skin is defined as skin with lower resistance to aggressions. Fragile skin can be classified into four categories up to its origin: physiological fragile skin (age, location), pathological fragile skin (acute and chronic), circumstantial fragile skin (due to environmental extrinsic factors or intrinsic factors such as stress) and iatrogenic fragile skin. This article includes the epidemiologic data, pathologic description of fragile skin with pathophysiological bases (mechanical and immunological role of skin barrier) and clinical description of fragile skin in atopic dermatitis, in acne, in rosacea, in psoriasis, in contact dermatitis and other dermatologic pathologies. This article includes also clinical cases and differential diagnosis of fragile skin (reactive skin) in face in adult population. In conclusion, fragile skin is very frequent worldwide and its prevalence varies between 25% and 52% in Caucasian, African and Asian population.
Subject(s)
Epidermis/pathology , Epidermis/physiology , Skin Diseases/pathology , Skin Diseases/physiopathology , Acne Vulgaris/pathology , Acne Vulgaris/physiopathology , Acne Vulgaris/therapy , Avena , Dermatitis, Atopic/pathology , Dermatitis, Atopic/physiopathology , Dermatitis, Atopic/therapy , Dermatitis, Contact/pathology , Dermatitis, Contact/physiopathology , Dermatitis, Contact/therapy , Eczema/pathology , Eczema/physiopathology , Eczema/therapy , Emollients/pharmacology , Emollients/therapeutic use , Epidermis/drug effects , Epidermis/immunology , Epidermis/physiopathology , Epidermolysis Bullosa/pathology , Epidermolysis Bullosa/physiopathology , Epidermolysis Bullosa/therapy , Humans , Phytotherapy , Plant Extracts/therapeutic use , Psoriasis/pathology , Psoriasis/physiopathology , Psoriasis/therapy , Retinoids/pharmacology , Retinoids/therapeutic use , Skin Diseases/immunology , Skin Diseases/therapyABSTRACT
This study was conducted to investigate the effects of different levels of dietary vitamin C on some skin mucus immune parameters, mucus antimicrobial activity and growth performance of Caspian roach (Rutilus rutilus caspicus) fry. Six hundred sixty Caspian roach (1.4 ± 0.02 g) fry were allocated to 12 tanks (55 fish per tank), and triplicate groups were fed diets containing 0, 1,000, 1,500 and 2,000 mg kg(-1) vitamin C for 60 days. At the end of the trial, the epidermal mucus protein level, alkaline phosphatase and antimicrobial activity against two gram-positive bacteria (Streptococcus faecium and Micrococcus luteus) and gram-negative bacteria (Escherichia coli and Serratia marcescens) as well as growth performance were measured. The results demonstrated that feeding on vitamin C significantly elevated skin mucus alkaline phosphatase and protein levels compared to the control group (P < 0.05). However, lysozyme activity was undetectable in both the vitamin C-fed roach fry and the control group. Skin mucus antimicrobial activity was increased following vitamin C administration, and the bacterial growth inhibition zones were significantly elevated in vitamin C-fed roach (P < 0.05). Similar results were obtained in case of the minimum inhibitory concentration of skin mucus. Also fish fed the control diet had a significantly lower weight gain, specific growth rate and condition factor compared to the other treatments (P < 0.05). These results revealed that dietary vitamin C beneficially affects the skin mucus immune parameters and growth performance of Caspian roach fry.
Subject(s)
Aquaculture/methods , Ascorbic Acid/pharmacology , Cyprinidae/growth & development , Cyprinidae/immunology , Dietary Supplements , Epidermis/immunology , Immunity, Mucosal/drug effects , Alkaline Phosphatase/blood , Analysis of Variance , Animals , Bacteria/immunology , Iran , Survival Analysis , Weight Gain/drug effectsABSTRACT
To increase our understanding of psoriasis, we used high-throughput complementary DNA sequencing (RNA-seq) to assay the transcriptomes of lesional psoriatic and normal skin. We sequenced polyadenylated RNA-derived complementary DNAs from 92 psoriatic and 82 normal punch biopsies, generating an average of â¼38 million single-end 80-bp reads per sample. Comparison of 42 samples examined by both RNA-seq and microarray revealed marked differences in sensitivity, with transcripts identified only by RNA-seq having much lower expression than those also identified by microarray. RNA-seq identified many more differentially expressed transcripts enriched in immune system processes. Weighted gene coexpression network analysis (WGCNA) revealed multiple modules of coordinately expressed epidermal differentiation genes, overlapping significantly with genes regulated by the long noncoding RNA TINCR, its target gene, staufen-1 (STAU1), the p63 target gene ZNF750, and its target KLF4. Other coordinately expressed modules were enriched for lymphoid and/or myeloid signature transcripts and genes induced by IL-17 in keratinocytes. Dermally expressed genes were significantly downregulated in psoriatic biopsies, most likely because of expansion of the epidermal compartment. These results show the power of WGCNA to elucidate gene regulatory circuits in psoriasis, and emphasize the influence of tissue architecture in both differential expression and coexpression analysis.
Subject(s)
Epidermis/physiology , Psoriasis/genetics , Transcriptome/genetics , Case-Control Studies , Cytoskeletal Proteins/genetics , Down-Regulation/genetics , Down-Regulation/immunology , Epidermis/immunology , Epidermis/pathology , Gene Expression Profiling , High-Throughput Nucleotide Sequencing , Humans , Interleukin-17/genetics , Keratinocytes/pathology , Keratinocytes/physiology , Kruppel-Like Factor 4 , Kruppel-Like Transcription Factors/genetics , Oligonucleotide Array Sequence Analysis , Psoriasis/immunology , Psoriasis/pathology , RNA, Long Noncoding/genetics , RNA-Binding Proteins/genetics , Transcription Factors/genetics , Tumor Suppressor ProteinsABSTRACT
Atopic dermatitis (AD) is characterized by epidermal tight junction (TJ) defects and a propensity for Staphylococcus aureus skin infections. S. aureus is sensed by many pattern recognition receptors, including Toll-like receptor 2 (TLR2). We hypothesized that an effective innate immune response will include skin barrier repair, and that this response is impaired in AD subjects. S. aureus-derived peptidoglycan (PGN) and synthetic TLR2 agonists enhanced TJ barrier and increased expression of TJ proteins, claudin-1 (CLDN1), claudin-23 (CLDN23), occludin, and Zonulae occludens 1 (ZO-1) in primary human keratinocytes. A TLR2 agonist enhanced skin barrier recovery in human epidermis wounded by tape stripping. Tlr2(-/-) mice had a delayed and incomplete barrier recovery following tape stripping. AD subjects had reduced epidermal TLR2 expression as compared with nonatopic subjects, which inversely correlated (r=-0.654, P=0.0004) with transepidermal water loss (TEWL). These observations indicate that TLR2 activation enhances skin barrier in murine and human skin and is an important part of a wound repair response. Reduced epidermal TLR2 expression observed in AD patients may have a role in their incompetent skin barrier.
Subject(s)
Dermatitis, Atopic/metabolism , Epidermis/metabolism , Tight Junctions/metabolism , Toll-Like Receptor 2/metabolism , Animals , Antibodies, Neutralizing/pharmacology , Bacterial Proteins/pharmacology , Dermatitis, Atopic/immunology , Dermatitis, Atopic/pathology , Epidermis/immunology , Epidermis/pathology , Female , Foreskin/cytology , Humans , Keratinocytes/cytology , Keratinocytes/immunology , Keratinocytes/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Peptidoglycan/pharmacology , Permeability , RNA, Messenger/metabolism , Tight Junctions/immunology , Tight Junctions/pathology , Toll-Like Receptor 1/genetics , Toll-Like Receptor 1/immunology , Toll-Like Receptor 1/metabolism , Toll-Like Receptor 2/agonists , Toll-Like Receptor 2/genetics , Transcutaneous Electric Nerve Stimulation , Wound Healing/physiologyABSTRACT
Astragalus membranaceus (AM) is one of the most popular health-promoting herbs in East Asia, and has been used in traditional medicine for more than 2000 years. This study was performed to examine whether AM suppresses atopic dermatitis (AD)-like skin lesions in BALB/c mice. Seven-week-old female BALB/c mice were sensitized with 1-chloro-2,4-dinitrobenzene (DNCB) to induce allergic dermatitis. Skin sections were stained with hematoxylin and eosin (H&E) to assess epidermal and dermal hyperplasia, which were determined by measuring the thicknesses of the epidermis and dermis, respectively. The serum immunoglobulin G (IgE) concentration was quantified by enzyme-linked immunosorbent assay (ELISA). In addition, the levels of interleukins (IL)-4, -5, -6, and -13 and tissue necrosis factor (TNF)-α were measured in mouse serum. Significance was determined by one-way analysis of variance (ANOVA). Topical AM markedly improved the AD skin lesions in DNCB-induced mice. The AD skin lesions were significantly thinner in the AM treatment group compared with untreated controls, and the hyperkeratosis disappeared. Topical treatment of AM also restored nuclear factor-κB (NF-κB) expression. In addition, the serum IgE level was reduced. AM suppressed the expression of Th2 cytokines (IL-4, -5, -6, and -13) and significantly decreased the TNF-α level. AM is effective for treating AD by regulating cytokines. AM may be an alternative or complementary therapeutic option for treating patients with AD. More in-depth studies are necessary to clarify the mechanisms of AM.
Subject(s)
Astragalus propinquus/immunology , Dermatitis, Atopic/drug therapy , Administration, Cutaneous , Animals , Dermatitis, Atopic/immunology , Dermis/immunology , Epidermis/immunology , Female , Hyperkeratosis, Epidermolytic/immunology , Immunoglobulin E/blood , Interleukins/immunology , Mice , Mice, Inbred BALB C , NF-kappa B/immunology , Phytotherapy , Tumor Necrosis Factor-alpha/immunologyABSTRACT
The therapeutic efficacy of the novel immunomodulator FTY720 (Fingolimod), alone and in combination with betamethasone ointment, was examined in the NC/Nga mouse model of spontaneous steroid-resistant dermatitis. Male NC/Nga mice which had developed severe dermatitis were divided into six groups: 1) a biweekly betamethasone group (betamethasone ointment, twice a week), 2) a daily betamethasone group (betamethasone ointment, six times a week), 3) an FTY720 group (FTY720, orally, three times a week), 4) a biweekly combination group (oral FTY720 plus betamethasone ointment, twice a week), 5) a daily combination group (oral FTY720 plus betamethasone ointment, six times a week) and 6) a placebo group (vehicle alone). The therapeutic efficacy was evaluated in terms of severity of dermatitis, epidermal hypertrophy, accumulation and degranulation of mast cells and infiltrated CD3+ T cells into the dermis after 4 weeks of treatment. Biweekly and daily betamethasone treatments had little effect, confirming that the dermatitis was steroid-resistant. In the FTY720 and biweekly combination groups, the dermatitis showed no marked improvement. In the daily combination group, the dermatitis was significantly (p<0.05, Mann-Whitney U-test) improved as compared with the FTY720 group, biweekly and daily betamethasone groups and placebo group. Further, epidermal hypertrophy and accumulation of mast cells were suppressed. Therefore, combination therapy with FTY720 and daily betamethasone ointment is a promising candidate for treatment of steroid-resistant atopic dermatitis.
Subject(s)
Betamethasone/therapeutic use , Dermatitis/drug therapy , Drug Resistance/drug effects , Epidermis/drug effects , Glucocorticoids/therapeutic use , Immunologic Factors/therapeutic use , Propylene Glycols/therapeutic use , Sphingosine/analogs & derivatives , Animals , Ascomycota/chemistry , Betamethasone/administration & dosage , Betamethasone/pharmacology , Biological Products/administration & dosage , Biological Products/pharmacology , Biological Products/therapeutic use , Dermatitis/immunology , Dermatitis/pathology , Epidermis/immunology , Epidermis/pathology , Fingolimod Hydrochloride , Glucocorticoids/administration & dosage , Glucocorticoids/pharmacology , Hypertrophy/drug therapy , Immunologic Factors/administration & dosage , Immunologic Factors/pharmacology , Male , Mast Cells/metabolism , Mice , Mice, Inbred Strains , Phytotherapy , Propylene Glycols/administration & dosage , Propylene Glycols/pharmacology , Sphingosine/administration & dosage , Sphingosine/pharmacology , Sphingosine/therapeutic use , Steroids , Treatment OutcomeABSTRACT
Topical photodynamic therapy (PDT) causes localized phototoxicity and has been shown both in vitro and in humans to have immunomodulatory and immunosuppressive effects. We report a case of localized bullous pemphigoid (BP) developing after PDT. Although BP has been reported to develop following cutaneous insults such as surgery, radiotherapy, psoralen ultraviolet A (PUVA) and ultraviolet B phototherapy, PDT has not previously been reported as a trigger. Possible mechanisms include direct mechanical injury to the basement membrane and subsequent autoantibody formation, an indirect immunomodulatory effect of PDT, or most likely, precipitation of BP in individuals with pre-existing low titres of epidermal autoantibodies (so-called subclinical BP). PDT should be added to the list of possible exogenous triggers for BP and this condition should be considered if blistering develops following PDT.
Subject(s)
Autoantibodies/immunology , Basement Membrane/immunology , Basement Membrane/injuries , Epidermis/immunology , Pemphigoid, Bullous/chemically induced , Pemphigoid, Bullous/immunology , Photochemotherapy/adverse effects , Aged, 80 and over , Basement Membrane/pathology , Bowen's Disease/drug therapy , Bowen's Disease/immunology , Bowen's Disease/pathology , Epidermis/pathology , Female , Humans , Skin Neoplasms/drug therapy , Skin Neoplasms/immunology , Skin Neoplasms/pathologyABSTRACT
Atopic dermatitis (AD) is characterized by highly pruritic, chronic, relapsing inflammatory skin lesions. Furthermore, therapeutic choices are limited, especially in long-standing cases, despite its increasing prevalence. This study was performed to examine the clinical efficacy and the therapeutic mechanism underlying the effects of Actinidia arguta (hardy kiwi) fruit extract in an animal model of AD. To examine the effects of A. arguta extract on AD, 2-chloro-1,3,5-trinitrobenzene-treated NC/Nga mice were orally administered A. arguta extract (100 mg/kg/day), tacrolimus (1 mg/kg/day), or dexamethasone (3 mg/kg/day) for 8 weeks. Skin severity scores, epidermal thickening, mast cell infiltration and degranulation, total serum immunoglobulin (Ig) isotypes (IgE, IgG(1)), and cytokine (interleukin [IL]-4 and interferon [IFN]-gamma) and Toll-like receptor (TLR) (TLR-2, TLR-4, and TLR-9) expressions were examined in each of the study groups. Orally administered A. arguta extract significantly reduced clinical dermatitis severity, epidermal thickness, mast cell dermal infiltration and degranulation, and total levels of serum IgE and IgG(1). Furthermore, this suppression of total serum IgE and IgG(1) levels was accompanied by a decrease in IL-4 and an increase in IFN-gamma expression in skin and splenocytes. Interestingly, TLR-9 expression was increased by oral A. arguta extract. This study confirms that A. arguta extract has potential as a dietary therapeutic agent for the treatment of AD. Furthermore, our findings suggest that its clinical efficacy and mode of action against AD are associated with the modulation of biphasic T-helper (Th) 1/Th2 cytokines, with the inhibition of Th2-mediated IgE overproduction, and possibly with the up-regulation of TLR-9.
Subject(s)
Actinidia , Dermatitis, Atopic/drug therapy , Mast Cells/drug effects , Phytotherapy , Plant Extracts/therapeutic use , Skin/drug effects , Administration, Oral , Animals , Dermatitis, Atopic/chemically induced , Dermatitis, Atopic/pathology , Dexamethasone/pharmacology , Epidermis/drug effects , Epidermis/immunology , Fruit , Immunoglobulin E/blood , Immunoglobulin G/blood , Interferon-gamma/metabolism , Interleukin-4/metabolism , Male , Mast Cells/metabolism , Mice , Models, Animal , Plant Extracts/pharmacology , Severity of Illness Index , Skin/immunology , Skin/pathology , Tacrolimus/pharmacology , Th1 Cells/metabolism , Th2 Cells/metabolism , Toll-Like Receptor 9/metabolism , Trinitrobenzenes , Up-RegulationABSTRACT
Whereas high-dose ultraviolet B (UVB) is detrimental to the epidermal permeability barrier, suberythemal doses of UVB are used to treat atopic dermatitis (AD), which is characterized by defective permeability barrier and antimicrobial function. As epidermal permeability barrier and antimicrobial peptide (AMP) expression are coregulated and interdependent functions, we hypothesized that suberythemal doses of UVB exposure could regulate AMP expression in parallel with permeability barrier function. Hairless mice were exposed to 40 mJ cm(-2) UVB (about 1/2 minimal erythema dose) daily for 1 or 3 days. Twenty-four hours after the last exposure, epidermal barrier function was assessed and skin specimens were taken for western blotting, immunohistochemistry, and quantitative reverse transcription-PCR for mouse beta-defensin (mBD)-2, mBD3 and cathelin-related antimicrobial peptide (CRAMP). mRNA levels of the vitamin D receptor (VDR), 1alpha-hydroxylase and key epidermal lipid synthetic enzymes were also quantified. After 3 days of UVB exposure, acceleration of barrier recovery and augmentation in expression of epidermal differentiation markers (for example, involucrin and filaggrin) occurred in parallel with increased mBD2, mBD3, and CRAMP expression at both the mRNA and protein level. VDR, 1alpha-hydroxylase, and the major epidermal lipid synthetic enzymes were also upregulated. When an inhibitor of 1alpha, 25 dihydroxyvitamin D(3) formation, ketoconazole, was applied immediately after UVB exposure, the cutaneous vitamin D system was inhibited, which in turn blocked epidermal lipid synthesis, AMP expression, and permeability barrier homeostasis, suggesting that the beneficial effect of low-dose UVB depends, at least in part, on activation of the cutaneous vitamin D system. Our results provide new insights into the mechanisms whereby low-dose UVB comprises effective therapy for AD.
Subject(s)
Antimicrobial Cationic Peptides/pharmacology , Epidermis/immunology , Epidermis/radiation effects , Animals , Cathelicidins , Cell Differentiation , Cholecalciferol/metabolism , Female , Immunohistochemistry , Ketoconazole/pharmacology , Lipids/chemistry , Mice , Mice, Hairless , Models, Biological , Permeability , Receptors, Calcitriol/metabolism , Ultraviolet RaysABSTRACT
BACKGROUND: Sensitization to atopens is an early phenomenon that overlaps with the onset of atopic dermatitis (AD) in infancy. Early epidermal barrier impairment may facilitate the epicutaneous penetration of atopens. OBJECTIVE: To correlate transepidermal water loss (TEWL) and aeroallergen sensitization in infants with AD. METHODS: In this cross-sectional study we enrolled 59 AD children and 30 controls aged 3-12 months. Transepidermal water loss in uninvolved skin, specific immunoglobulin E, atopy patch test (APT) and skin prick tests were performed with respect to seven aeroallergens, i.e., Dermatophagoides pteronyssinus, D. farinae, cat, dog, birch pollen, ambrosia, and cockroach. Environmental conditions were assessed by a questionnaire, and the house dust mite (HDM) concentration was determined in dust samples. RESULTS: Eighty-nine percent of AD infants had a positive APT vs one out of eleven controls. AD infants had a significantly higher mean TEWL than controls (27.4 vs 11.1 g/m(2)/h, P < 0001). Children with two or more positive APT had higher TEWL than the others (31.1 vs 19.0 g/m(2)/h, P < 0.025). No correlation was found between indoor APT results and exposure to HDM, cats, and dogs at home. CONCLUSIONS: This study confirms the high prevalence of delayed sensitization to indoor and outdoor aeroallergens in AD infants, and shows that the higher the TEWL, the higher the prevalence of sensitization to aeroallergens. These data are in favor of a major role of a constitutive epidermal barrier impairment in determining early atopen sensitization in infants with AD.